• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Down1.29% Nasdaq Down3.25%

    Sunesis Pharmaceuticals, Inc. (SNSS)

    0.79 Up 0.02(3.28%) Feb 5, 4:00PM EST
    ProfileGet Profile for:
    Sunesis Pharmaceuticals, Inc.
    395 Oyster Point Boulevard
    Suite 400
    South San Francisco, CA 94080
    United States - Map
    Phone: 650-266-3500
    Fax: 650-266-3501
    Website: http://www.sunesis.com

    Index Membership:N/A
    Full Time Employees:39

    Business Summary 

    Sunesis Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of oncology therapeutics for the treatment of solid and hematologic cancers. The company is developing vosaroxin, an anti-cancer quinolone derivative for the treatment of acute myeloid leukemia (AML). It has completed a Phase III, randomized, double-blind, and placebo-controlled trial of vosaroxin in combination with cytarabine in patients with relapsed or refractory AML. The company also completed a Phase II single-agent trial of vosaroxin in platinum-resistant ovarian cancer. In addition, it is involved in the initiation of an investigator-sponsored trial of vosaroxin in combination with decitabine in older patients with untreated AML and high-risk myelodysplastic syndrome. Sunesis Pharmaceuticals, Inc. has a collaboration agreement with Biogen Idec to discover, develop, and commercialize small molecule inhibitors of the human protein Raf kinase; and licensing agreements with Millennium to provide worldwide license to develop and commercialize preclinical inhibitors of phosphoinositide-dependent kinase-1. The company was founded in 1998 and is headquartered in South San Francisco, California.

    Key Statistics

    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Sunesis Pharmaceuticals, Inc.

    Corporate Governance 
    Sunesis Pharmaceuticals, Inc.’s ISS Governance QuickScore as of Jul 1, 2015 is 8. The pillar scores are Audit: 2; Board: 5; Shareholder Rights: 6; Compensation: 10.
    Brought to you by Institutional Shareholder Services (ISS)

    Key Executives 
    Mr. Daniel N. Swisher Jr., 53
    Chief Exec. Officer, Pres and Director
    Mr. Eric H. Bjerkholt , 56
    Chief Financial Officer, Exec. VP of Corp. Devel. & Fin. and Corp. Sec.
    Mr. Gene C. Jamieson ,
    VP of Technical Operations
    Dr. Mary G. Bolton M.D., Ph.D.,
    VP of Clinical Devel.
    Dr. Deborah A. Thomas Ph.D.,
    VP of Regulatory Affairs & Medical Writing
    Amounts are as of Dec 31, 2014 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders